Please use this identifier to cite or link to this item:
|Title:||The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials.|
|Authors:||Segelov, E;Chan, David L;Shapiro, J;Price, Timothy J;Karapetis, C S;Tebbutt, Niall C;Pavlakis, N|
|Affiliation:||St Vincent's Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.|
Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia.
Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia.
The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia.
Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia.
Austin Health, VIC 3084, Australia.
|Citation:||British Journal of Cancer 2014; 111(6): 1122-31|
|Abstract:||Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy.Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis.Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82-0.91, P<0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67-0.74, P<0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03-2.78, P<0.00001). Grade 3/4 toxicity was increased with OR 2.34. Considering by subgroups, EGFR inhibitors (EGFR-I) in the second-line setting and anti-angiogenic therapies (both in second-line and third-line and beyond settings) all improved overall survival, PFS and ORR. EGFR-I in third-line settings improved PFS and ORR but not OS.The use of biologic agents in mCRC after first-line treatment is associated with improved outcomes but increased toxicity.|
|Internal ID Number:||25072258|
|Subjects:||Angiogenesis Inhibitors.adverse effects.therapeutic use|
Antibodies, Monoclonal.adverse effects.therapeutic use
Biological Therapy.adverse effects
Colorectal Neoplasms.drug therapy.pathology
Randomized Controlled Trials as Topic
Receptor, Epidermal Growth Factor.antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor.antagonists & inhibitors
Vascular Endothelial Growth Factor A.antagonists & inhibitors
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.